Investment Firm Sectoral Asset Management Inc Sees Changes in Q3 2022 vs. Q4 2022 Fund Holdings
Ava Hoppe | 7 May, 2023
Sectoral Asset Management Inc is a well-known investment firm that manages over $10 billion of assets. The firm recently filed its Form 13F with the SEC, which discloses its portfolio holdings as of the end of Q3 2022 and Q4 2022. The 13F report shows the changes in the firm's holdings between the two quarters, and it provides insight into the firm's investment strategy.
In this article, we will take a deep dive into Sectoral Asset Management's Q3 2022 vs. Q4 2022 13F Holdings Comparison report. We will provide an overview of the changes in the firm's holdings, identify the top stocks in the portfolio, and analyze the firm's investment strategy.
Overview of Sectoral Asset Management's 13F Holdings Comparison
Sectoral Asset Management's 13F Holdings Comparison report for Q3 2022 vs. Q4 2022 is a comprehensive document that lists the firm's holdings by stock symbol, issuer name, option type, and value. The report shows that the firm increased its holdings in some stocks, decreased its holdings in others, and sold out of some entirely.
The report indicates that the firm's total portfolio value decreased from $4.3 billion in Q3 2022 to $3.9 billion in Q4 2022. It is important to note that the changes in the portfolio value are not necessarily a reflection of the fund's performance, as they can also be attributed to other factors such as capital flows and market conditions.
Top Stocks in Sectoral Asset Management's Portfolio
According to the report, the top five stocks in Sectoral Asset Management's portfolio are:
1. R1 RCM Inc (RCM)
2. Evolent Health Inc (EVH)
3. HealthEquity Inc (HQY)
4. UnitedHealth Group Inc (UNH)
5. Biomarin Pharmaceutical Inc (BMRN)
R1 RCM Inc is the largest holding in the portfolio, representing 3.77% of the total portfolio value. The firm increased its holdings in R1 RCM Inc by 17.1% from Q3 2022 to Q4 2022, indicating a bullish stance on the stock.
Evolent Health Inc and HealthEquity Inc are the second and third largest holdings in the portfolio, respectively. While the firm increased its position in Evolent Health Inc, it decreased its holdings in HealthEquity Inc. This suggests that the firm has a more favorable outlook on Evolent's growth prospects as compared to HealthEquity.
UnitedHealth Group Inc and Biomarin Pharmaceutical Inc are the fourth and fifth largest holdings in the portfolio. Sectoral Asset Management reduced its holdings in UnitedHealth Group Inc, while increasing its position in Biomarin Pharmaceutical Inc. This shows that the firm is betting on the growth prospects of Biomarin Pharmaceutical Inc while reducing its exposure to UnitedHealth Group Inc.
Sectoral Asset Management's Investment Strategy
Sectoral Asset Management's investment strategy revolves around identifying promising companies in the healthcare sector, particularly in the biotech and pharmaceutical industries. The firm's investment style involves a mix of both growth and value investing.
The Q3 2022 vs. Q4 2022 13F Holdings Comparison report indicates that Sectoral Asset Management has a bullish stance on the healthcare sector, particularly on biotech and pharmaceutical stocks. The firm increased its position in several biotech companies, including Prometheus Biosciences, Amylyx Pharmaceuticals, and Rallybio. It is clear from the report that Sectoral Asset Management believes in the long-term growth potential of these companies and their ability to solve critical healthcare challenges.
Conclusion
Sectoral Asset Management's Q3 2022 vs. Q4 2022 13F Holdings Comparison report provides valuable insight into the firm's investment strategy and its views on the healthcare sector. The report indicates that the firm is bullish on the healthcare sector, especially on biotech and pharmaceutical stocks. The firm's investment style is a mix of growth and value investing, and it is clear that it seeks to invest in companies that have the potential to make a significant impact on the healthcare industry.
Other Posts
- A Deep Dive into Sapience Investments, LLC's Q3 2022 vs. Q4 2022 13F Holdings
- Meyer Handelman Co Q3 2023 vs. Q4 2023 13F Holdings Comparison
- SeaBridge Investment Advisors LLC's Q3 2022 vs. Q4 2022 13F Holdings Comparison: Analyzing the Latest Changes in Holdings
- Focused Wealth Management, Inc Quarterly Holdings Comparison: Q4 2022 vs. Q1 2023
- Navigating the Infrastructure Investment Labyrinth: A Guide to Antin's 2023 Universal Registration Document
- Navigating the Winds of Change: G&S Capital LLC's Investment Strategy Evolution from Q4 2023 to Q1 2024
- Investment Insights: Chesley Taft & Associates LLC Q4 2022 vs. Q1 2023 13F Holdings Comparison
- Thompson Street Capital Partners Expands Biologics Portfolio with Isto Biologics Merger
- Westover Capital Advisors: Q2 2022 vs. Q3 2022 Holdings and Trends
- Sterling Capital Management LLC Q2 2019 vs. Q3 2019 13F Holdings Comparison